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Abstract 
 
Swedish healthcare quality registries are tools for the evaluation and improvement of clinical services and population-based 
research. There are presently 11 national quality registries that focus on psychiatric disorders; but none cover all 
neurodevelopmental disorders (NDDs) as defined by the International Statistical Classification of Diseases and Related Health Problems, 
10th Revision (ICD-10) and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Health care professionals 
have called for more user-friendly; time-saving; and clinically informative registers. 
To fill this gap, the NEUROPSYK Quality Register was established in 2014 by the Center of Neurodevelopmental 
Disorders at Karolinska Institutet. Initially, this was a clinical register of child and adolescent psychiatry for the Stockholm 
County Council. 
The main objectives of NEUROPSYK are to improve the assessment of and interventions used for individuals with NDDs 
by doing the following: 1) supporting adequate follow-up related to the implementation of existing regional and national 
guidelines for assessment and treatment; 2) providing clinical decision-making aids; and 3) conducting large-scale clinical 
epidemiological research. The registry incorporates all legal requirements for quality registries in Sweden. 
NEUROPSYK includes patients of all ages diagnosed with NDDs per the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition. These diagnoses include autism spectrum disorder, attention-deficit/hyperactivity disorder, intellectual 
disabilities, communication disorders, specific learning disorders, and motor disorders. Medication and behavioral 
interventions are recorded and patient outcomes over time are measured with the economical and user-friendly Clinical Global 
Impression tool, the Global Assessment of Functioning instrument, and patient-reported health-related quality of life. 
NEUROPSYK minimizes administrative work for health care professionals because it is integrated with structured digital 
patient records, thereby increasing the likelihood of high coverage and data quality. NEUROPSYK combines several strengths 
to exemplify a new generation of quality research registers for use in psychiatry and other areas of health care. 
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Read more about NEUROPSYK: http://ki.se/en/kind/neuropsyk-quality-registry-for-neurodevelopmental-disorders 
 
 
Background 
Approximately 10% of the general population is 
affected by neurodevelopmental disorders (NDDs) 
(1). Recently, NDD diagnoses have increased 
markedly in Sweden and elsewhere in the world, 
which has posed a challenge to many health care 
providers. For example, between 2001 and 2011, the 
prevalence of diagnosed autism spectrum disorder 
(ASD) increased 3.5-fold among Stockholm children 
between the ages of 0 and 17 years (2). The increase 
in the prevalence of ASD without intellectual 
disability was almost 8-fold, from 0.14% to 1.10%. In 
addition, the prescription of methylphenidate for 
attention-deficit/hyperactivity disorder (ADHD) 
increased from 1.2% in 2006 to 4.6% in 2014 among 
males between the ages of 10 and 17 years (3). In 
Sweden in 2014, a total of 58,600 individuals with 
ADHD were treated pharmacologically (4). 
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Regional and national health care authorities in 
Sweden have generated clinical guidelines for the 
assessment and treatment of NDDs to improve 
evidence-based practice and comparable services 
across providers and regions (5-7). However, no 
systematic means have yet been implemented to 
determine whether recommended diagnostic and 
treatment procedures are followed, and individuals in 
the health care system are not being tracked across 
their NDD diagnoses, ages, and types of service 
providers. To achieve this goal locally, regionally, and 
nationally, data about health care, outcomes, and 
patient pathways are needed. One efficient strategy 
to use to obtain this is the implementation of 
healthcare quality registries (QRs). 
QRs in Sweden serve as important tools for the 
evaluation and improvement of health care services, 
and they provide a primary data source for 
epidemiological and longitudinal research (8-10). 
QRs contain individualized information about 
patients’ diagnoses, diagnostic assessments, medical 
interventions, treatment outcomes, and patient-
reported outcome measures. In 2016, a total of 108 
different national QRs were approved and 
monitored by the Swedish Association of Local 
Authorities and Regions (11). Eleven of these QRs 
included psychiatric disorders. With the exception of 
children with ADHD, a majority of patients with 
NDDs are not included in the existing registries at all 
(Table 1). For example, individuals with ASD in the 
normative intelligence range are not yet included in 
current QRs, and there are no QRs to cover any 
language or speech disorders. Most current registers 
cover only certain NDD diagnoses (e.g., only 
ADHD), only patients referred to a specific type of 
organization (e.g., child and adolescent psychiatry), 
or only adults. Long-term follow-up of patients’ 
pathways in health care is needed throughout 
childhood and adolescence and into adulthood. 
Information is needed from the different professions 
involved (e.g., pediatricians, neurologists, 
psychologists, speech therapists) as well as from 
different care units (e.g., pediatric units, habilitation 
centers, child- and adolescent psychiatry, speech 
therapy, adult psychiatry). Hence, there is a need to 
implement a registry that covers the full health care 
pathways and outcomes for patients with all NDDs 
across their lifetimes. 
 
 
 
TABLE 1. Overview of quality registries that include patients with psychiatric disorders in Sweden 
Registry name Registry focus Diagnoses included Ages  No. of patients in 
registry (n) 
Completeness 
(%) 
BipoläR Bipolar disorders Bipolar disorders All ages 8373 28% 
BUSA Attention-deficit/hyperactivity 
disorder 
Attention-deficit/hyperactivity disorder and 
attention deficit disorder 
All ages 5689 10% 
ECT Electroconvulsive therapy Not specified All ages 3664 89% 
HabQ Habilitation services Cerebral palsy, autism (low functioning), and 
other not specified diagnoses 
Children Cerebral palsy, 569; 
autism, 345; others, 
1120 
No information 
Kvalitetsstjärnan Psychosis and schizophrenia Psychosis and schizophrenia Adults 3000/year No information 
NEUROPSYK Neurodevelopmental disorders  Autism spectrum disorders, attention-
deficit/hyperactivity disorder and attention 
deficit disorder, dyslexia, Tourette 
syndrome, stuttering, etc. 
All ages 896 No information 
PsykosR Psychosis and schizophrenia Psychosis All ages 7923 23% 
RIKSÄT Eating disorders Eating disorders All ages 2600/year 90% 
Rättspsyk Forensic psychiatry Not specified Adults 1728 86% 
SBR Addictive behavior Addiction (e.g., opiates) Adults 4078 15% 
SIBeR Internet treatment Depression, phobias, etc. All ages No information No information 
Q-BUP Child and adolescent health care  All diagnoses Children 0 0% 
Information about the number of patients in each registry and the registry’s completeness has been retrieved from that registry’s annual report or from the National 
Board of Health and Welfare (Completeness 2015 - Comparisons between Swedish Healthcare Quality Registries and government-administered health registries) 
 
 
 
Objectives 
The NEUROPSYK Quality Register was established 
in 2014 by the Center of Neurodevelopmental 
Disorders at Karolinska Institutet, and it initially and 
formally considered a clinical register of child and 
adolescent psychiatry for Stockholm County 
Council. The register’s objective is to collect data for 
all patients who receive diagnoses within the NDD 
categories of the DSM-5 regardless of service 
provider or age, in the country of Sweden (Table 2). 
Current ICD-10 diagnoses are converted with the use 
of the recommended ICD-10 diagnosis synopses 
from the DSM-5. This includes ASD, ADHD, 
intellectual disabilities, communication disorders, 
specific learning disorders, and motor disorders (see 
Table 2). Due to the considerable comorbidity 
between these types of conditions and other 
psychiatric and somatic disorders, it is advantageous 
to include all NDD diagnoses and co-existing 
disorders in the same registry to enable follow-up for 
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all patients who are not included in other QRs at 
present. Service providers who are included or 
planned to be included are the following: child and 
adolescent psychiatry, adult psychiatry, habilitation 
services, speech therapy providers, pediatric 
neurology and medicine, and clinical genetics. 
 
 
 
TABLE 2. International Statistical Classification of Diseases and Related Health Problems; 10th Revision diagnoses included in NEUROPSYK 
DSM-5 Category 
 
ICD-10 diagnoses as defined in DSM-5 
 
Other relevant ICD-10 diagnoses included  
Intellectual disability F70; F71; F72; F73; F79  
Communication disorders F80.9; F80.0; F80.8 F98.5 
Autism spectrum disorders F84.0 F84.5; F84.1; F84.9 
Attention-deficit/hyperactivity disorder F90.2; F90.0; F90.1; F90.8; F90.9  
Learning disorders F81.0; F81.1; F81.2  
Motor disorders F82; F98.4; F95.2; F95.1; F95.0; F95.8; F95.9  
Other neurodevelopmental disorders F88; F89   
DSM-5; Diagnostic and Statistical Manual of Mental Disorders; Fifth Edition Category 
ICD-10; International Statistical Classification of Diseases and Related Health Problems; 10th Revision 
 
 
 
Methods 
Unlike traditional Swedish QRs, NEUROPSYK is 
integrated with patient medical records and requires 
minimal administrative work for health care 
professionals. This curtails any unnecessary 
workload and increases the likelihood of both high 
coverage of the target population and data validity. 
For all consenting patients, a limited number of 
essential and informative health measures are 
retrieved automatically. This allows for an accessible 
system that requires minimal administration. 
NEUROPSYK was first implemented in the largest 
Swedish county (Stockholm) through integration 
with the medical record software “Take Care,” which 
is used by both private and county council managed 
care units. Every 24 hours, data for the chosen 
variables are retrieved from the patient record 
database and sent via a secure health care connection 
to the registry platform, where they are saved and can 
be used for feedback to care providers on different 
levels. For example, service management can easily 
access online statistics related to resources used, 
treatments administered, and improvement in global 
functioning and quality of life over time for different 
patient groups. 
In addition to information about the patient (e.g., 
personal identity number, ICD-10 diagnosis), the 
registry includes data about each episode of patient 
contact with the care provider, including the 
following: the date of each visit, the profession(s) 
involved in the care (e.g., physician, psychologist, 
social worker, special education teacher), and the 
type of visit (e.g., home visit, group treatment, 
individual consultation) (Table 3). In addition, the 
registry includes information about what 
pharmacological treatments were prescribed (ATC 
codes) and the defined daily dose. Other treatments 
and interventions are coded using the Swedish 
classification of health interventions (i.e., the KVÅ 
code, which may refer to neuropsychiatric 
assessment, cognitive behavioral treatment, or 
patient education in a group). Process measures (e.g., 
medications, types of behavioral intervention), 
outcome measures (e.g., Clinical Global Impression, 
Global Assessment of Functioning), and patient 
reported data (e.g., EQ-5D/DISABKIDS) are 
included. 
NEUROPSYK also provides patient overviews, 
which are useful for clinical routines and easily 
accessible from the medical record through a single 
sign-on for authentication. The overview includes 
the patient’s diagnoses as well as his or her current 
health status (i.e., Global Assessment of 
Functioning), quality of life (i.e., EQ-
5D/DISABKIDS), medications, interventions, and 
health care contacts over time (Figure 1). The patient 
overview can be used to plan and follow up on 
interventions for the patient.  
NEUROPSYK can also be used for register-based 
research, provided that ethical approval is obtained 
for a specified research project and that the registry 
board has accepted the project. In principle, any 
researcher can access NEUROPSYK, and the same 
roles apply as for any Swedish QR. For example, the 
registry can be used to study characteristics of 
outpatients diagnosed with NDDs (e.g., trajectories, 
comorbidities, functioning, disability pension, quality 
of life). Furthermore, studies of the transition from 
child and adolescent health care to adult health care 
for persons with NDDs and adherence to clinical 
guidelines can be performed. Studies of the effects of 
perinatal and other environmental factors on NDDs 
can occur with the use of information from other 
QRs and national health statistics. 
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TABLE 3. Data retrieved from patient records in NEUROPSYK  
Variable Description 
Patient identification and diagnosis   
Personal identity number Unique 10-digit number including information about birthday 
(YYMMDD) and sex (male/female) 
International Statistical Classification of Diseases and Related Health 
Problems, 10th Revision diagnosis 
Primary and additional diagnoses 
Care provider–related information   
County County where the caregiver is located 
Health care unit/department Caregiver unit unique identity number 
Type of visit Home visit, group treatment, telephone contact, etc. 
Visit date/contact date All types of visits or contacts (consultations, home visits, phone 
calls, etc.) 
Number of professionals meeting patient Maximum of 5 professionals per visit 
Professions involved in the consultation Type of professions involved in patients' care (e.g., physician, 
psychologist, occupational therapist, social worker, special 
education teacher, speech therapist)  
Teatment and interventions   
Anatomic Therapeutic Chemical classification system (ATC code)  Pharmacological treatment  
Defined daily dose (DDD) Amount of each medication taken each day 
Klassifikation av vårdåtgärder code (KVÅ code) Swedish classification of health and medical interventions  
Clinician-rated measures 
 
Global Assessment of Functioning (GAF) Assessment of functioning for adults 
Children's Global Assessment Scale (CGAS) Assessment of functioning for children 0 to 18 years old 
Children's Global Assessment Scale for Developmental Disabilities 
(DD-CGAS)  
Assessment of functioning for children 0 to 18 years old 
Clinical Global Impression-Severity (CGI-S)  Severity of the condition 
Patient reported measures 
 
EQ-5D Self-reported health-related quality of life for adults 
DISABKIDS Proxy or self-reported health-related quality of life for children 
and adolescents 
 
 
 
 
FIGURE 1. Patient overview 
 
 
 
 
 
 
 
 
 
The variables in the registry were selected on the 
basis of current clinical guidelines and in response to 
the consensus of a reference group. The reference 
group consisted of 20 clinicians, stakeholders, and 
registry and information technology experts as well 
as policy makers (e.g., psychiatrists, pediatricians, 
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psychologists, speech therapists, researchers, 
managers, health care officials, experts on quality 
registries and information technology). The process 
started in 2011, with four reference group meetings 
held to discuss aims, variables, and technological 
solutions. Further discussions were held in smaller 
working groups, and a board consisting of 12 
members was formed. The NEUROPSYK board has 
representatives from health care (i.e., child and 
adolescent psychiatry, adult psychiatry, pediatric 
units, habilitation centers, speech therapy, and school 
nurses), research (i.e., psychiatrists, pediatricians, and 
psychologists), information technology experts, and 
non-governmental organizations. The register 
adheres to all legislative requirements for national 
QRs in Sweden, which are mainly delineated in the 
Swedish Patient Data Act. NEUROPSYK is a 
formally approved care register of the Stockholm 
County Council, and it has also been accepted by the 
Swedish Association of Local Authorities and 
Regions. 
 
Pilot project 
Starting in 2013, five care units participated in the 
development of registry routines and technological 
solutions. In 2015, the registry was integrated with 
the medical record system in Sweden’s largest county 
(Stockholm), and the QR was used by five pilot units 
as a regional system. The development process was 
done in close collaboration with each of the five 
public and private health service representatives and 
providers, interested organizations, and existing 
psychiatric registries in Stockholm County Council 
and beyond (e.g., BUSA, a national quality registry 
for structured follow-ups of patients with ADHD 
both children and adults; see Table 1). The 
development of the registry was guided by legal 
experts from the Stockholm County Council to 
ensure compliance with the legal requirements 
related to patient rights and data safety.  
The pilot use of this registry was an iterative 
process that involved technicians, multi-professional 
clinicians from various departments, and researchers. 
The following objectives were kept in mind: 1) to 
optimize information technology and connect to the 
electronic clinical file system in clinical reality; 2) to 
enhance user feasibility; 3) to generate automatic 
informative statistics and reports for clinicians; 4) to 
collect experiences with the adequate 
implementation of the register into existing clinical 
routines; 5) to encounter and solve user reservations; 
and 6) to examine the use of the registry in terms of 
clinical and research utility and validity. 
NEUROPSYK is currently operating as a regional 
quality registry in Stockholm County so that its 
feasibility can be examined; the eventual goal is to 
implement it as a national QR. As of October 2016, 
NEUROPSYK contained more than 1000 patients 
with NDDs who were enrolled from 13 different 
units. 
 
Future plans and developments 
An evaluation of the pilot project is planned that will 
focus on validation, data quality, and the user 
experience. Another objective is to develop a way for 
this system to integrate with the national platform, 
with the goal of transferring data from patient record 
systems all over Sweden into NEUROPSYK. The 
recruitment of care providers from all over Sweden 
as well as the training of clinicians in how to assess 
global functioning is ongoing. A long-term goal is to 
collect more data regarding which diagnosis-specific 
standardized instruments are most often used by 
clinicians. We are continuously lobbying for 
structured variables to be created by the county 
councils for this purpose. 
Feedback from patients and their family members 
is invaluable to improve quality of care. In 
NEUROPSYK, web-based questionnaires assess 
patient-reported outcome measures related to health 
status, quality of life, and satisfaction with care via a 
home computer or a tablet in a health care waiting 
room. Outcomes of patient-reported measures can 
be used for planning, treatment, and follow-up 
before, during, and after consultations. However, the 
collection of patient-reported measures has not been 
implemented in most of the participating care 
providers; this is planned for the future. 
 
Conclusions 
QRs in Sweden are unique resources to improve the 
quality of healthcare and to provide large amounts of 
data for epidemiological research. Despite these 
benefits, QRs have been criticized for increasing 
administrative work for health care professionals. 
Managers and health care recipients have called for 
more user-friendly and time-saving systems for 
following up on the quality of care received. As a 
result, a new generation of QRs with a higher degree 
of integration with patients’ medical records is 
emerging. NEUROPSYK is an example of the next 
generation of QRs, and it has been developed with 
the aim of providing an efficient tool for the 
improvement of health care. NEUROPSYK includes 
real-time follow-up evaluations of health care 
interventions; this differs from traditional QRs, 
which record patient responses via separate web-
based forms that may be separated from the health 
care experience being assessed by weeks or months. 
With the use of real-time information related to 
actual treatment pathways for these patients, 
improved collaboration among different health care 
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units and professions can be achieved and may result 
in reduced waiting times, the earlier discovery of 
NDDs, and earlier intervention. The continuous 
collection of relevant clinical data from both public 
and private providers will also make it possible for 
health care authorities and politicians to optimize 
health care by allowing for the more effective 
allocation of resources to the care of children with 
NDDs and their families.  
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